The
Patients who took the drug, which the drugmaker will market under the brand name Zavzpret, reported pain relief in as little as 15 minutes in a Phase 3 study,
Zavegepant also was superior to placebo at providing freedom from pain at two hours after a dose. It is the first calcitonin gene-related peptide receptor antagonist nasal spray for migraines, the company said.
"When a migraine hits, it has a significant negative impact on a person's daily life,"
Zavegepant is expected to be available to consumers by prescription in July.
The drug was well-tolerated in trials. Common side effects include taste disorders, nausea, nasal discomfort and vomiting,
A Phase 3, double-blind, randomized, placebo-controlled, trial published in The Lancet Neurology found that two hours after treatment, 24% of patients who took 10 milligramsof zavegepant had pain freedom compared with 15% in the placebo group.
Forty percent reported freedom from their most bothersome symptom, compared with 31% in the placebo group.
Migraines affect about 39 million people in
Migraines can cause severe pain, nausea, vomiting, sensitivity to light and sound, and sensory disturbances called aura, which can include flashes of light, blind spots and tingling sensations.
Copyright 2023 United Press International, Inc. (UPI). Any reproduction, republication, redistribution and/or modification of any UPI content is expressly prohibited without UPI's prior written consent., source